PainReform falls after update on lead drug trial

PRF Technologies

07/06/2023 22:24

** Shares of Israel-based drug developer PainReform Ltd
 PRFX.O  fall ~14% to $0.41 after the bell 
    ** Says its supplier of active pharmaceutical ingredient
(API) has received a deficiency notice from the U.S. FDA,
related to a file representing the manufacturing process and
production facility for the API
    ** PRFX says second part of late-stage trial for lead drug
PRF-110 is expected to begin once the deficiency notice has been
resolved, adding that none of the issues raised relate to
PRF-110 
    ** PRF-110 is being tested to provide postoperative pain
relief in patients undergoing surgery to treat a type of joint
deformity 
    ** As of last close, PRFX shares up ~16% this year

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))